As a tumor with a high degree of malignancy, liver cancer has a high probability of recurrence and metastasis after surgery. Therefore, after liver cancer surgery, many surgeons will choose to go for postoperative interventional therapy based on the prognostic assessment of the tumor, and go for postoperative treatment of the liver to prevent recurrence and metastasis of liver cancer, or small residuals after surgery. The role of intervention is to do regional arterial perfusion chemotherapy and embolization to the liver locally after liver cancer surgery, which has the following two functions: 1) to kill the tumor cells in the budding state through local high concentration of chemotherapy drugs; 2) to do moderate embolization with iodine oil drugs, which has a characteristic that liver cancer cells can selectively swallow iodine oil. Therefore, after the patient has undergone interventional surgery, the patient can be detected by CT examination whether there are residual or small lesions that are more difficult to be detected in other examinations. According to the statistics, the five-year survival rate of liver cancer patients is about 15%-40%, and within two years after liver cancer surgery, about 60%-80% of patients will have metastasis or recurrence. For patients with metastasis and recurrence, it may be due to the fact that tumor cells have already entered other parts of the body through blood circulation in the early stage of the tumor, including the liver and other tissues outside the liver. After the surgery, the tumor cells may start to grow in time when the immunity of human body decreases or under the influence of various hormones or factors. If the tumor cells are not completely killed by the body’s own immune function, they may metastasize and recur.